Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 6/2020

Open Access 01-06-2020 | Ticagrelor | Review

Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials

Authors: Katie Linden, Jonathan Mailey, Aileen Kearney, Ian B. A. Menown

Published in: Advances in Therapy | Issue 6/2020

Login to get access

Abstract

Introduction

A large number of important clinical trials in cardiology were published or presented at major international conferences during 2019. This paper aims to offer a concise overview of these significant advances and to put them into clinical context.

Methods

Trials presented at the major international cardiology meetings during 2019 were reviewed including The American College of Cardiology (ACC), Euro PCR, The European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), and the American Heart Association (AHA). In addition to this a literature search identified several other publications eligible for inclusion based on their relevance to clinical cardiology, their potential impact on clinical practice and on future guidelines.

Results

A total of 70 trials met the inclusion criteria. New interventional and structural data include trials examining use of drug-coated balloons in patients with acute myocardial infarction (MI), interventions following shockable cardiac arrest, mechanical circulatory support in cardiogenic shock complicating MI, intervention in stable coronary artery disease, surgical or percutaneous revascularisation strategies in left main coronary artery disease, revascularisation strategy in ST elevation MI, transcatheter aortic valve replacement in low-risk patients, and percutaneous mitral or tricuspid valve interventions. Preventative cardiology data included the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin), proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors (evolocumab), bempedoic acid, and novel approaches to the management of hypertension. Antiplatelet data included trials evaluating both the optimal length of course and combination of antiplatelet agents and regimes including combination antithrombotic therapies for patients with atrial fibrillation. Heart failure data included trials of sacubitril–valsartan in heart failure with preserved ejection fraction and the use of SGLT2 inhibitors in patients with heart failure but without diabetes. Electrophysiology data included trials examining alcohol in atrial fibrillation and the use of wearable fitness devices for identifying atrial fibrillation.

Conclusion

This article presents key clinical trials completed during 2019 and should be valuable to clinicians and researchers working in cardiology.
Literature
1.
Urban P, Mehran R, Morice MC, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J. 2019;40(31):2632–53.PubMedPubMedCentralCrossRef
2.
Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020;382(13):1208–18.PubMedCrossRef
3.
Menown IBA, Mamas MA, Cotton JM, et al. First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry. Int J Cardiol Heart Vasc. 2020;26:100472.PubMedPubMedCentral
4.
Buiten R, Ploumen E, Zocca P, et al. Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels. J Am Med Assoc Cardiol. 2019;4(7):659–69.
5.
Zaman A, de Winter RJ, Kogame N, et al. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019;393(10175):987–97.PubMedCrossRef
6.
Xu B, Saito Y, Baumbach A, et al. 2-year clinical outcomes of an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent compared with a durable-polymer everolimus-eluting stent. JACC Cardiovasc Interv. 2019;12(17):1679–87.PubMedCrossRef
7.
Stone GW, Kappetein AP, Sabik JF, et al. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med. 2019;381:1820–30.PubMedCrossRef
8.
Holm NR, Mäkikallio T, Lindsay MM, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet. 2020;395(10219):191–9.PubMedCrossRef
9.
Thuijs DJ, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394:1325–34.PubMedCrossRef
10.
Vos N, Fagel N, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction. J Am Coll Cardiol Cardiovasc Interv. 2019;12(17):1691–9.CrossRef
11.
Burzotta F, Leone AM, Aurigemma C, et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically-intermediate coronary stenosis: a single-center trial. J Am Coll Cardiol Cardiovasc Interv. 2020;13(1):49–58.CrossRef
12.
Ali ZA, Nef H, Escaned J, et al. Safety and effectiveness of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: the disrupt CAD II study. Circn Cardiovasc Interv. 2019;12(10):e008434.CrossRef
13.
Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381:1411–21.PubMedCrossRef
14.
Hochman J. International study of comparative health effectiveness with medical and invasive approaches. Presented at the American Heart Association Annual Scientific Sessions, 16 November 2019; Philadelphia, PA.
15.
Bangalore S. International study of comparative health effectiveness with medical and invasive approaches–chronic kidney disease. Presented at the American Heart Association Annual Scientific Sessions, 16 November 2019; Philadelphia, PA.
16.
Thourani VH. Five-year outcomes from PARTNER 2A trial: transcatheter vs. surgical aortic valve replacement in intermediate-risk patients. Presented at the Transcatheter Cardiovascular Therapeutics meeting, 28 September 2019; San Francisco, CA.
17.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–15.PubMedCrossRef
18.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–705.PubMedCrossRef
19.
Makkar RR. PARTNER 3 low-risk computed tomography substudy: subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves. Presented at the Transcatheter Cardiovascular Therapeutics meeting, 27th September 2019; San Francisco, CA.
20.
Dangas GD, Tijssen JG, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–9.PubMedCrossRef
21.
Lanz J, Kim WK, Walther T, et al. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. Lancet. 2019;394:1619–28.PubMedCrossRef
22.
Van Belle E, Vincent F, Labreuche J, et al. Balloon-expandable versus self-expanding transcatheter aortic valve replacement: a propensity-matched comparison from the France-TAVI Registry. Circulation. 2020;141:243–59.
23.
Makkar RR, Yoon SH, Leon MB, et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke. J Am Med Assoc. 2019;321:2193–202.CrossRef
24.
Baumbach A, Hildick-Smith D, Mylotte D, et al. Safety, feasibility, and acute performance of the Leaflex Performer when used pre-TAVI in aortic stenosis patients: the Leaflex feasibility study. Presented at EuroPCR, 22nd May 2019; Paris, France.
25.
Kang DH, Park SJ, Lee SA, et al. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med. 2020;382:111–9.PubMedCrossRef
26.
Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379(24):2297–306.PubMedCrossRef
27.
Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail. 2019;21(12):1619–27.PubMedCrossRef
28.
Stone G, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379(24):2307–18.PubMedCrossRef
29.
Mack MJ. COAPT: 3-year outcomes from a randomized trial of the MitraClip in patients with heart failure and severe secondary mitral regurgitation. Presented at the Transcatheter Cardiovascular Therapeutics meeting, 28 September 2019; San Francisco, CA.
30.
Asch FM. Heart Failure and secondary mitral regurgitation: echocardiographic outcomes from the COAPT Trial. Presented at The American College of Cardiology Scientific Sessions, 17 March 2019; New Orleans, LA.
31.
32.
Hausleiter J. Early procedural outcomes from subjects treated with next-generation MitraClip (NTR/XTR) system: initial observations from the Global EXPAND study. Presented at EuroPCR, 21 May 2019; Paris, France.
33.
Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74(24):2998–3008.PubMedCrossRef
34.
Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394(10213):2002–111.PubMedCrossRef
35.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–288.PubMedCrossRef
36.
Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628–39.PubMedCrossRef
37.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.
38.
Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138(5):458–68.PubMedPubMedCentralCrossRef
39.
Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139:2528–36.PubMedCrossRef
40.
Aminian A, Zajichek A, Arterburn D, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. J Am Med Assoc. 2019;322(13):1271–82.CrossRef
41.
Schwalm JD, McCready T, Lopez-Jaramillo P, et al. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster randomised controlled trial. Lancet. 2019;394(10205):1231–42.PubMedCrossRef
42.
43.
White WB, Wakefield DB, Moscufo N, et al. Effects of intensive versus standard ambulatory blood pressure control on cerebrovascular outcomes in older people (INFINITY). Circulation. 2019;140(20):1626–35.PubMedPubMedCentralCrossRef
44.
Kuck KH. MODERATO II: a double-blind randomized trial of cardiac neuromodulation therapy in patients with hypertension. Presented at Transcatheter Cardiovascular Therapeutics meeting 2019, 28 September 2019; San Francisco, CA.
45.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.PubMedCrossRef
46.
Jukema JW, Szarek M, Zijlstra LE, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74(9):1167–76.PubMedCrossRef
47.
Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–39.PubMedCrossRef
48.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.PubMedCrossRef
49.
Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452–62.PubMedCrossRef
50.
Linden K, McQuillan C, Brennan P, Menown IBA, et al. Advances in clinical cardiology 2018: a summary of key clinical trials. Adv Ther. 2019;36(7):1549–73.PubMedPubMedCentralCrossRef
51.
Scott Wright R. Inclisiran for subjects with ACSVD and elevated low density lipoprotein cholesterol—ORION-10. Presented at the American Heart Association Annual Scientific Sessions 2019, 16 November 2019. Philadelphia, PA.
52.
Ray KK. Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk equivalent—results of the phase 3 ORION-11 trial. Presented at the European Society of Cardiology Congress 2019, 2 September 2019. Paris, France.
53.
Goldberg AC. Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia and high cardiovascular risk: the CLEAR wisdom trial. Presented at American College of Cardiology Annual Scientific Sessions 2019, 18 March 2019; New Orleans, LA.
54.
Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–32.PubMedCrossRef
55.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.PubMedCrossRef
56.
Budoff MJ. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy—EVAPORATE. Presented at the American Heart Association Annual Scientific Sessions 2019, 18 November 2019. Philadelphia, PA.
57.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMedCrossRef
58.
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colcicine after myocardial infarction. N Engl J Med. 2019;381:2497–2505.
59.
Shah B. Effects of acute colchicine administration prior to percutaneous coronary intervention: the COLCHICINE-PCI randomized trial. Presented at the American Heart Association Annual Scientific Sessions 2019, 17 November 2019. Philadelphia, PA.
60.
Bjoerklund. SWEDEHEART—Secondary prevention medication after coronary artery bypass surgery and long-term mortality: a longitudinal population-based study from the SWEDEHEART registry. Presented at the European Society of Cardiology Congress 2019, 3 September 2019. Paris, France.
61.
Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032–42.PubMedCrossRef
62.
Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. J Am Med Assoc. 2019;321:2428–37.CrossRef
63.
Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs. 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. J Am Med Assoc. 2019;321:2414–27.CrossRef
64.
Kirtane AJ. EVOLVE Short DAPT: a single arm study of 3-month DAPT in patients at high bleeding risk treated with a bioabsorbable polymer-based everolimus-eluting stent. Presented at Transcatheter Cardiovascular Therapeutics meeting 2019, 26 September 2019; San Francisco, CA.
65.
Franzone A, McFadden E, Leonardi S, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am Coll Cardiol. 2019;74(18):2223–34.PubMedCrossRef
66.
Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309–20.PubMedCrossRef
67.
Schüpke S, Neumann F, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524–34.PubMedCrossRef
68.
69.
Claassens DM, Vos GJ, Bergmeyer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621–31.PubMedCrossRef
70.
Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509–24.PubMedCrossRef
71.
Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335–433.PubMedCrossRef
72.
Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019;380:1825–33.PubMedCrossRef
73.
Lemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380:1397–407.PubMedCrossRef
74.
Hausenloy DJ, Kharbanda RK, Moller UK, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet. 2019;394:1415–24.PubMedPubMedCentralCrossRef
75.
Perera D. PROTECCT: a randomized trial of emergency CTA in patients with possible ACS and intermediate levels of HS-troponin elevation. Presented at Transcatheter Cardiovascular Therapeutics meeting 2019, 27 September 2019; San Francisco, CA.
76.
Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139(10):1249–58.PubMedCrossRef
77.
Amin AP, Spertus JA, Curtis JP, et al. The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. 2020;141:273–84.PubMedCrossRef
78.
Voskoboinik A, Prabhu S, Ling LH, et al. Alcohol and atrial fibrillation: a sobering review. J Am Coll Cardiol. 2016;68:2567–76.PubMedCrossRef
79.
Voskoboinik A, Kalman JM, Nicholls T, et al. Impact of alcohol abstinence in moderate drinkers with atrial fibrillation: results from the alcohol-AF randomized controlled trial. Presented at American College of Cardiology Annual Scientific Sessions 2019, 18 March 2019; New Orleans, LA.
80.
Matsumura-Nakano Y, Shizuta S, Komasa A, et al. An open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond one year after coronary stent implantation: the OAC-ALONE study. Circulation. 2019;139:604–16.PubMedCrossRef
81.
Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103–13.PubMedCrossRef
82.
83.
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–48.PubMedCrossRef
84.
Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. J Am Med Assoc. 2019;322:1085–95.CrossRef
85.
McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan, versus valsartan in women compared to men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020;141:338–51.
86.
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.PubMedCrossRef
87.
McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.PubMedCrossRef
88.
89.
Halliday BP, Wassall R, Lota AS. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open label, pilot, randomised trial. Lancet. 2019;393(10166):61–73.PubMedPubMedCentralCrossRef
90.
Shavelle DM. Pulmonary artery pressure-guided therapy for ambulatory heart failure patients in clinical practice; 1-year outcomes from the CardioMEMS post-approval study. Presented at American College of Cardiology Annual Scientific Sessions 2019, 17 March 2019; New Orleans, LA.
91.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(41):2793–867.PubMedCrossRef
92.
Haanschoten D. Long-term outcome of the defibrillator after primary angioplasty (DAPA) trial. Presented at European Society of Cardiology Congress, 3 September 2019. Paris, France.
93.
Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med. 2019;380(20):1895–905.PubMedCrossRef
Metadata
Title
Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials
Authors
Katie Linden
Jonathan Mailey
Aileen Kearney
Ian B. A. Menown
Publication date
01-06-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01355-5

Other articles of this Issue 6/2020

Advances in Therapy 6/2020 Go to the issue

Original Research

Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study

Original Research

Management of Patients with Coronary Artery Disease in Lithuania: a Comparison with Other Central Eastern European Countries Based on Data From the International CLARIFY Registry

Review

Limited Utility for Benzodiazepines in Chronic Pain Management: A Narrative Review

Original Research

A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies

Original Research

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis

Original Research

Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits